ClearPoint Neuro Announces Initiation of Limited Market Release for the SmartFrame OR™ Stereotactic System More than Ten Operating Room Procedures Complete with Multiple Sites Reordering and Scheduling Cases SOLANA BEACH, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced it has initiated the Limited Market Release for its SmartFrame OR™ Stereotactic System. “Expanding ClearPoint’s portfolio beyond the MRI into t...
Rhythm Pharmaceuticals to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024 BOSTON, April 24, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, May 7, 2024 to report its first quarter 2024 financial results and provide a corporate update. To access the live conference call, participants may register . Wh...
• Plunging sales & growing losses, severe price cuts & layoffs, failed FSD, M2 dropped for Robotaxi, and more, confirm that Elon Musk won't fix Tesla's most serious problems—which he created. • Yet he still demands his "unfathomable" pay package be restored, and his feckless, captured Tesla Board is doing exactly what he wants. • What Tesla’s Board should do, what it should have done years ago, is fire Elon Musk, the single greatest risk to Tesla’s future.
ClearPoint Neuro to Announce First Quarter 2024 Results May 7, 2024 SOLANA BEACH, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it will release financial results for its 2024 first quarter on Tuesday, May 7th, after the market close. Investors and analysts are invited to listen to the live broadcast review of the Company’s 2024 first quarter on Tuesday, May 7th, at 4:30 p.m. Eastern time (1:30 p.m. Pacifi...
Generation Bio Announces the Acceptance of Five Abstracts and an Invited Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, today announced that six abstracts highlighting preclinical data from its cell-targeted lipid nanoparticle (ctLNP) and immune-quiet DNA (iqDNA) platforms have been accepted for presentation, including one oral presentation, at the American Society of Gen...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.